Central Trust Company’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.67M Sell
308,862
-5,626
-2% -$150K 0.17% 96
2025
Q4
$7.83M Sell
314,488
-85,365
-21% -$2.15M 0.15% 102
2025
Q3
$10.2M Sell
399,853
-54,685
-12% -$1.35M 0.21% 82
2025
Q2
$11M Buy
454,538
+23,044
+5% +$537K 0.25% 67
2025
Q1
$10.9M Buy
431,494
+36,044
+9% +$943K 0.27% 69
2024
Q4
$10.5M Sell
395,450
-68,310
-15% -$1.85M 0.26% 70
2024
Q3
$13.4M Sell
463,760
-6,827
-1% -$199K 0.31% 66
2024
Q2
$13.2M Sell
470,587
-7,887
-2% -$217K 0.32% 63
2024
Q1
$13.3M Sell
478,474
-24,296
-5% -$674K 0.33% 61
2023
Q4
$14.5M Sell
502,770
-26,168
-5% -$791K 0.38% 53
2023
Q3
$17.5M Sell
528,938
-20,581
-4% -$728K 0.51% 42
2023
Q2
$20.2M Sell
549,519
-1,656
-0.3% -$64.5K 0.56% 41
2023
Q1
$22.5M Sell
551,175
-2,557
-0.5% -$110K 0.66% 38
2022
Q4
$28.4M Sell
553,732
-9,240
-2% -$443K 0.87% 31
2022
Q3
$24.6M Sell
562,972
-4,508
-0.8% -$219K 0.84% 31
2022
Q2
$29.8M Buy
567,480
+5,156
+0.9% +$263K 0.98% 25
2022
Q1
$29.1M Sell
562,324
-12,903
-2% -$669K 0.83% 30
2021
Q4
$34M Sell
575,227
-5,402
-0.9% -$268K 0.96% 22
2021
Q3
$25M Sell
580,629
-984
-0.2% -$43.6K 0.89% 26
2021
Q2
$22.8M Sell
581,613
-4,685
-0.8% -$182K 0.83% 25
2021
Q1
$21.2M Sell
586,298
-8,800
-1% -$312K 0.83% 26
2020
Q4
$21.9M Sell
595,098
-31,141
-5% -$1.14M 0.9% 24
2020
Q3
$21.8M Buy
626,239
+26,168
+4% +$917K 0.99% 20
2020
Q2
$18.6M Buy
600,071
+7,513
+1% +$255K 0.93% 23
2020
Q1
$18.4M Buy
592,558
+12,616
+2% +$430K 1.12% 18
2019
Q4
$21.6M Sell
579,942
-5,616
-1% -$200K 1.1% 21
2019
Q3
$20M Sell
585,558
-32,146
-5% -$1.17M 1.12% 20
2019
Q2
$25.2M Sell
617,704
-13,936
-2% -$553K 1.43% 16
2019
Q1
$25.5M Sell
631,640
-1,096
-0.2% -$43.9K 1.52% 13
2018
Q4
$26.2M Sell
632,736
-5,928
-0.9% -$246K 1.74% 6
2018
Q3
$26.7M Sell
638,664
-2,206
-0.3% -$84.9K 1.55% 10
2018
Q2
$22.1M Sell
640,870
-2,562
-0.4% -$87.6K 1.41% 15
2018
Q1
$21.7M Sell
643,432
-8,403
-1% -$289K 1.38% 14
2017
Q4
$22.4M Sell
651,835
-8,970
-1% -$306K 1.36% 14
2017
Q3
$22.4M Buy
660,805
+1,509
+0.2% +$48.5K 1.45% 13
2017
Q2
$21M Sell
659,296
-52,177
-7% -$1.65M 1.39% 12
2017
Q1
$23.1M Sell
711,473
-21,671
-3% -$683K 1.54% 8
2016
Q4
$22.6M Sell
733,144
-14,201
-2% -$434K 1.56% 10
2016
Q3
$24M Buy
747,345
+35,980
+5% +$1.2M 1.75% 5
2016
Q2
$23.8M Buy
711,365
+4,510
+0.6% +$144K 1.78% 6
2016
Q1
$19.9M Buy
706,855
+28,944
+4% +$827K 1.57% 8
2015
Q4
$20.8M Sell
677,911
-13,290
-2% -$418K 1.71% 7
2015
Q3
$20.6M Buy
691,201
+817
+0.1% +$26.2K 1.79% 5
2015
Q2
$22M Buy
690,384
+12,501
+2% +$407K 1.73% 4
2015
Q1
$22.4M Buy
677,883
+55,142
+9% +$1.75M 1.8% 6
2014
Q4
$18.4M Sell
622,741
-20,878
-3% -$599K 1.5% 11
2014
Q3
$18.1M Sell
643,619
-26,160
-4% -$734K 1.43% 10
2014
Q2
$18.9M Buy
669,779
+13,846
+2% +$395K 1.49% 10
2014
Q1
$20M Buy
655,933
+38,919
+6% +$1.16M 1.65% 10
2013
Q4
$17.9M Sell
617,014
-41,267
-6% -$1.2M 1.5% 10
2013
Q3
$17.9M Buy
658,281
+15,616
+2% +$425K 1.62% 9
2013
Q2
$17.1M Buy
+642,665
New +$17.8M 1.62% 12

Other funds holding PFE

Central Trust Company's PFE Position: Q1 2026 in Review

Central Trust Company reduced its Pfizer (PFE) stake by 1.8% in Q1 2026, selling an estimated $150K and leaving 308,862 shares worth $8.67M. The position accounts for 0.17% of the portfolio, ranked #96.

Central Trust Company first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $34M in Q4 2021. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Central Trust Company held 308,862 shares of Pfizer worth $8.67M as of Q1 2026.
  • Central Trust Company sold 5,626 Pfizer shares in Q1 2026, an estimated $150K.
  • Pfizer made up 0.17% of Central Trust Company's portfolio in Q1 2026, its #96 holding.
  • Central Trust Company first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Central Trust Company's Pfizer position peaked at $34M in Q4 2021.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Central Trust Company's 13F filing for Q1 2026, filed 17 Apr 2026.